Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.58 and traded as high as $0.63. Protagenic Therapeutics shares last traded at $0.55, with a volume of 110,680 shares.
Protagenic Therapeutics Stock Down 4.0 %
The business's 50 day simple moving average is $0.47 and its 200-day simple moving average is $0.58. The company has a market cap of $9.49 million, a price-to-earnings ratio of -2.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
Get Protagenic Therapeutics alerts:Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last issued its earnings results on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent quarter. Institutional investors own 3.47% of the company's stock.Protagenic Therapeutics Company Profile
(Get Rating)
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Further Reading
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.